NeoPharm Suspends Glioblastoma Trials Following Disappointing Phase III Results
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm seeks meeting with FDA to determine path forward.
You may also be interested in...
Neopharm Glioblastoma Drug Will Require Another Phase III Study, FDA Says
Decision by agency to require another trial of cintredekin besudotox comes after the pivotal Phase III PRECISE study failed to meet its primary endpoint.
Neopharm Glioblastoma Drug Will Require Another Phase III Study, FDA Says
Decision by agency to require another trial of cintredekin besudotox comes after the pivotal Phase III PRECISE study failed to meet its primary endpoint.
Lilly To Continue Development Of Enzastaurin Despite Termination Of Glioblastoma Trial
Company remains optimistic and will pursue other indications, Lilly told “The Pink Sheet” DAILY.